Evidence based approach for the management of mixed hyperlipidaemia

Atherosclerosis

Volumn 137, Issue SUPPL., 1998, Pages

  Gaw, Allan ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Cholesterol; Coronary heart disease; Risk factors

Indexed keywords

BEZAFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY RISK; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; TREATMENT PLANNING;

CORONARY DISEASE; EVIDENCE-BASED MEDICINE; HUMANS; HYPERLIPIDEMIAS;

EID: 0031781494     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00318-3     Document Type: Conference Paper

References (27)

1. HMSO. The Health of the Nation. A Strategy for Health in England. HMSO, London 1992.
2. Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialised countries since 1950. World Health Stat Q 1988;41:155-78.
3. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495.
4. Simpson HS, Williamson CM, Olivecrona T, et al. Postprandial lipaemia, fenofibrate and coronary artery disease. Atherosclerosis 1990;85:193.
5. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: Results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994;24:444.
6. Assmann G, Schulte H. Results and conclusions of the Prospective Cardiovascular Münster study. In: Assmann G, editor. Lipid Metabolism Disorders and Coronary Heart Disease. Munich: MMV Medizin Verlag, 1989.
7. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383.
8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995;333:1301.
9. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment. Circulation 1992;85:37-45.
10. Gaw A, Packard CJ, Murray EF, Lindsay GM, Griffin BA, Caslake MJ, Vallance BD, Lorimer AR, Shepherd J. Effects of simvastatin on apo B metabolism and LDL subfraction distribution. Arterioscler Thromb 1993;13:170.
11. Gaw A, Packard CJ, Lindsay GM, et al. Overproduction of small very low density lipoproteins (Sf 20-60) in primary moderate hypercholesterolemia: Relationships between apolipoprotein B kinetics and plasma lipoproteins. J Lipid Res 1995;36:158.
12. Gaw A, Shepherd J. Fibric acid derivatives. Curr Opin Lipidol 1991;2:39.
13. Kissebah AH, Adams PW, Harrigan, Wynn V. The mechanism of action of clofibrate and tetranicotinylfructose on the kinetics of plasma free fatty acid and triglyceride transport in Type IV and Type V hypertriglyceridemia. Eur J Clin Invest 1974;4:163.
14. Dixon JL, Ginsberg HN. Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: Information from cultured liver cells. J Lipid Res 1993;34:167.
15. Stewart JM, Packard CJ, Lorimer AR, Boag DE, Shepherd J. Effects of bezafibrate on receptor mediated and receptor independent low density catabolism on type II hyperlipoproteinemic subjects. Atherosclerosis 1982;44:355.
16. Shepherd J, Caslake MJ, Lorimer AR, Vallance BD, Packard CJ. Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects. Arteriosclerosis 1985;5:162.
17. Ericsson C-G, Hamsten A, Nilsson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347:849.
18. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma lipoproteins in normal humans. J Lipid Res 1981;23:97.
19. Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density lipoprotein subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 1990;83:59.
20. Kleinman Y, Oschry Y, Eisenberg S. Abnormal regulation of LDL receptor activity and abnormal cellular metabolism of hypertriglyceridaemic low density lipoprotein: Normalization with bezafibrate therapy. Eur J Clin Invest 1987;17:538.
21. de Graaf J, Mak-hemmers HLM, Hectors MPC, Demacker PNM, Hendricks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991;11:298.
22. Tan CE, Forster L, Caslake MJ, et al. Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfraction patterns in normolipemic men and women. Arterioscler Thromb Vase Biol 1995;15:183.
23. Caslake MJ, Packard CJ, Gaw A, et al. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 1993;13:702.
24. Franceschini G, Lovate MR, Manzoni C, et al. Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein(LDL) subclass distribution and LDL-cell interaction. Atherosclerosis 1995;114:61.
25. Mellies M, McGovern M. Ongoing and planned clinical trials for atherosclerosis prevention and regression. Exp Opin Invest Drugs 1994;3:1189.
26. Steiner G. The dyslipoproteinemias of diabetes. Atherosclerosis 1994;110:27.
27. Keech A. Lipids and diabetes mellitus: an opportunity to reduce cardiovascular disease risk. Abstract from the 66th congress of the European Atherosclerosis Society, Florence 1996.